BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 06, 2006
 |  BioCentury  |  Finance

Hustle and bustle at AIM

There is a growing belief among companies that London's Alternative Investment Market has shed the credibility concerns that once plagued it and is now an acceptable stock market for the blue chip international institutions that biotechs need. Last week, three companies listed on AIM, including two non-U.K. names, while a British company said it would move from LSE's main list to AIM.

"AIM is attractive because virtually all of the blue chip institutions have a proportion of their funds invested in AIM companies, and we are seeing increasing interest in this market from Continental European investors," Juliet Thompson, a banker with Nomura Code Securities, told BioCentury. "A significant proportion of the companies that we have brought to AIM in the last year are incorporated outside the U.K. and have been attracted to London because of its lower regulatory burden and convenient access to a broad spread of institutional investors."

Irish gastrointestinal reprofiler AGI Therapeutics plc (ISE:A9I; LSE:AGI, Dublin, Ireland), which was established in 2003 by former Elan Corp. plc executives, made its debut on AIM and Dublin's IEX exchange last Monday, raising £29.2 million ($50.9 million) through a placing of shares to new and existing shareholders.

"AIM was the ideal choice for AGI because of the availability of international funds, the market's light regulatory regime, the lower costs than the main markets and speedier transactions,"...

Read the full 1121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >